Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-GITR-L is a type of Glucocorticoid-induced TNF receptor (GITR) ligand fusion protein (GITRL-FP) that functions as an agonist of GITR. GITR is a co-stimulatory receptor belonging to the TNF receptor superfamily, expressed on various immune cells, particularly regulatory T cells (Tregs) and natural killer (NK) cells, and its expression is upregulated on activated T cells. By mimicking the natural GITR ligand (GITRL), Ad-GITR-L aims to stimulate GITR, thereby enhancing the activity of effector T-cells and inhibiting the suppressive function of Tregs. This dual mechanism promotes an anti-tumor immune response, making it a promising target for cancer immunotherapy. Preclinical studies have indicated that GITRL-FP can expand antigen-specific CD8 T cells, deplete Tregs, and generate long-lasting anti-tumor memory.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ad-GITR-L.